人甲状腺旁素1型受体的结构特征

doi:10.3866/PKU.WHXB201204192

摘要/Abstract

摘要：

人甲状腺旁素1 型受体(PTH1R)是骨形成相关的B类G蛋白偶联受体, 其底物甲状腺旁腺素(PTH)及类似物具有抗骨质疏松作用. 由于此类受体的三维结构难以进行实验测定, 本文采用同源模建的方法, 完整构建了胞外区、跨膜区及其它相关区域, 并通过对接研究, 阐明复合物的氢键、疏水性相互作用及其与底物的相互作用关系和关键位点. 为进一步设计和发展此类药物提供理论依据.

关键词: 甲状腺旁素1型受体, 甲状腺旁素, 同源模建, 甲状腺旁素复合物

Abstract:

Parathyroid hormone 1 receptor (PTH1R) is a member of the class B G-protein coupled receptor (B-GPCR) family and is involved in bone formation. Its substrate parathyroid hormone (PTH) and its analogues are being developed as anti-osteoporosis therapeutics. The structure-based rational drug design of PTH1R substrates has been hampered by the lack of experimentally determined three-dimensional (3D) structures from techniques such as nuclear magnetic resonance (NMR) and X-ray crystallography. Here, we have constructed a 3D model of PTH1R including its extracellular domain (ECD), transmembrane domain (TM) and other domains using a homology modeling approach. In addition, to capture the ligand-receptor interactions, we have manually docked human parathyroid hormone (1-34) into the top scoring receptor model, and subjected the PTH-PTH1R complex to an unconstrained energy minimization. The integral 3D receptor model provides an easier way to understand the interactions involved at the TM, ECD, and other domains. Furthermore, the parameters of hydrogen bonding, hydrophobic, and other interactions from the ligand-receptor model, enabled us to elucidate the important interactions between PTH (1-34) and PTH1R. This ligand-receptor model could potentially serve as a tool for structure-based virtual screening in the development of non-peptide based anti-osteoporosis drugs.

Key words: Parathyroid hormone 1 receptor, Parathyroid hormone, Homology modeling, PTH-PTH1R complex

点击下载补充材料PDF格式文件

林克江, 朱冬吉, 冷勇敢, 尤启冬. 人甲状腺旁素1型受体的结构特征[J]. 物理化学学报, 2012, 28(07), 1783-1789. doi: 10.3866/PKU.WHXB201204192

LIN Ke-Jiang, ZHU Dong-Ji, LENG Yong-Gan, YOU Qi-Dong. Structural Characterization of Human Parathyroid Hormone 1 Receptor[J]. Acta Phys. -Chim. Sin. 2012, 28(07), 1783-1789. doi: 10.3866/PKU.WHXB201204192

链接本文: https://www.whxb.pku.edu.cn/CN/10.3866/PKU.WHXB201204192

https://www.whxb.pku.edu.cn/CN/Y2012/V28/I07/1783

参考文献

(1) Potts, J. T.; Gardella, T. J. Annals of the New York Academy of Sciences 2007, 1117, 196. doi: 10.1196/annals.1402.088
(2) Potts, J. T. J. Endocrinol. 2005, 187, 311. doi: 10.1677/joe.1.06057
(3) Murray, T. M.; Rao, L. G.; Divieti, P.; Bringhurst, F. R. Endocr. Rev. 2005, 26, 78. doi: 10.1210/er.2003-0024
(4) Gardella, T. J.; Juppner, H. Trends Endocrinol. Metab. 2001, 12,210. doi: 10.1016/S1043-2760(01)00409-X
(5) Juppner, H.; Abou-Samra, A. B.; Freeman, M.; Kong, X. F.;Schipani, E.; Richards, J.; Kolakowski, L. F., Jr.; Hock, J.; Potts,J. T., Jr.; Kronenberg, H. M. Science 1991, 254, 1024. doi: 10.1126/science.1658941
(6) Pioszak, A. A.; Harikumar, K. G.; Parker, N. R.; Miller, L. J.;Xu, H. E. J. Biol. Chem. 2010, 285, 12435. doi: 10.1074/jbc.M109.093138
(7) Pioszak, A. A.; Xu, H. E. Proc. Natl. Acad. Sci. U. S. A. 2008,105, 5034. doi: 10.1073/pnas.0801027105
(8) Jin, L.; Briggs, S. L.; Chandrasekhar, S.; Chirgadze, N. Y.;Clawson, D. K.; Schevitz, R.W.; Smiley, D. L.; Tashjian, A. H.;Zhang, F. J. Biol. Chem. 2000, 275, 27238.
(9) Rolz, C.; Pellegrini, M.; Mierke, D. F. Biochemistry 1999, 38,6397. doi: 10.1021/bi9829276
(10) Discovery Studio, 2.5; Accelrys Software Inc.: San Diego, US,2010.
(11) Pellegrini, M.; Bisello, A.; Rosenblatt, M.; Chorev, M.; Mierke,D. F. Biochemistry 1998, 37, 12737. doi: 10.1021/bi981265h
(12) Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen,S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.;Weis,W. I.; Kobilka, B. K.; Stevens, R. C. Science 2007, 318, 1258.doi: 10.1126/science.1150577
(13) Kerfeld, C. A.; Anwar, H. P.; Interrante, R.; Merchant, S.;Yeates, T. O. J. Mol. Biol. 1995, 250, 627. doi: 10.1006/jmbi.1995.0404
(14) Thompson, J. D.; Higgins, D. G.; Gibson, T. J. Nucleic Acids Res. 1994, 22, 4673. doi: 10.1093/nar/22.22.4673
(15) Spassov, V.; Yan, L.; Szalma, S. J. Phys. Chem. B 2002, 106,8726. doi: 10.1021/jp020674r
(16) Im,W.; Lee, M. S.; Brooks, C. L. J. Comput. Chem. 2003, 24,1691. doi: 10.1002/jcc.10321
(17) Luthy, R.; Bowie, J. U.; Eisenberg, D. Nature 1992, 356, 83.doi: 10.1038/356083a0
(18) Lovell, S. C.; Davis, I.W.; Arendall,W. B., III; de Bakker, P. I.;Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D.C. Proteins 2003, 50, 437. doi: 10.1002/prot.10286
(19) Adams, A. E.; Bisello, A.; Chorev, M.; Rosenblatt, M.; Suva, L.J. Mol. Endocrinol. 1998, 12, 1673. doi: 10.1210/me.12.11.1673
(20) Fletcher, R.; Powell, M. J. D. The Computer Journal 1963, 6,163.
(21) Grippo, L.; Lucidi, S. Mathematical Programming 1997, 78,375.
(22) MOE, 2009; Chemical Computing Group: Montreal, Canada,2009.
(23) Clark, A. M.; Labute, P. J. Chem. Inf. Model. 2007, 47, 1933.doi: 10.1021/ci7001473
(24) Greenberg, Z.; Bisello, A.; Mierke, D. F.; Rosenblatt, M.;Chorev, M. Biochemistry 2000, 39, 8142. doi: 10.1021/bi000195n
(25) Sali, A. Mol. Med. Today 1995, 1, 270. doi: 10.1016/S1357-4310(95)91170-7
(26) Dean, T.; Khatri, A.; Potetinova, Z.;Willick, G. E.; Gardella, T.J. J. Biol. Chem. 2006, 281, 32485. doi: 10.1074/jbc.M606179200
(27) Barbier, J. R.; Gardella, T. J.; Dean, T.; MacLean, S.;Potetinova, Z.; Whitfield, J. F.;Willick, G. E. J. Biol. Chem.2005, 280, 23771. doi: 10.1074/jbc.M500817200
(28) Mierke, D. F.; Maretto, S.; Schievano, E.; DeLuca, D.; Bisello,A.; Mammi, S.; Rosenblatt, M.; Peggion, E.; Chorev, M.Biochemistry 1997, 36, 10372. doi: 10.1021/bi970771o
(29) Caporale, A.; Biondi, B.; Schievano, E.;Wittelsberger, A.;Mammi, S.; Peggion, E. Eur. J. Pharmacol. 2009, 611, 1. doi: 10.1016/j.ejphar.2009.03.040
(30) Pioszak, A. A.; Parker, N. R.; Gardella, T. J.; Xu, H. E. J. Biol. Chem. 2009, 284, 28382. doi: 10.1074/jbc.M109.022905
(31) Piserchio, A.; Bisello, A.; Rosenblatt, M.; Chorev, M.; Mierke,D. F. Biochemistry 2000, 39, 8153. doi: 10.1021/bi000196f
(32) Hoare, S. R. Drug Discov. Today 2005, 10, 417. doi: 10.1016/S1359-6446(05)03370-2
(33) Mierke, D. F.; Mao, L.; Pellegrini, M.; Piserchio, A.; Plati, J.;Tsomaia, N. Biochem. Soc. Trans. 2007, 35, 721. doi: 10.1042/BST0350721
(34) Rolz, C.; Mierke, D. F. Biophys. Chem. 2001, 89, 119. doi: 10.1016/S0301-4622(00)00222-2
(35) Barbier, J. R.; MacLean, S.; Whitfield, J. F.; Morley, P.;Willick,G. E. Biochemistry 2001, 40, 8955. doi: 10.1021/bi010460k
(36) Luck, M. D.; Carter, P. H.; Gardella, T. J. Mol. Endocrinol.1999, 13, 670. doi: 10.1210/me.13.5.670
(37) Gardella, T. J.; Juppner, H.;Wilson, A. K.; Keutmann, H. T.;Abou-Samra, A. B.; Segre, G. V.; Bringhurst, F. R.; Potts, J. T.,Jr.; Nussbaum, S. R.; Kronenberg, H. M. Endocrinology 1994,135, 1186. doi: 10.1210/en.135.3.1186
(38) Bisello, A.; Adams, A. E.; Mierke, D. F.; Pellegrini, M.;Rosenblatt, M.; Suva, L. J.; Chorev, M. J. Biol. Chem. 1998,273, 22498. doi: 10.1074/jbc.273.35.22498
(39) Monticelli, L.; Mammi, S.; Mierke, D. F. Biophys. Chem. 2002,95, 165. doi: 10.1016/S0301-4622(02)00005-4
(40) Gensure, R. C.; Shimizu, N.; Tsang, J.; Gardella, T. J. Mol. Endocrinol. 2003, 17, 2647. doi: 10.1210/me.2003-0275

[1]	邓玉玲,余璐,黄强. 人类蛋白激酶组的多靶点分子对接系统[J]. 物理化学学报, 2016, 32(9): 2355 -2363 .
[2]	张青青, 姚其正, 张生平, 毕乐明, 周之光, 张骥. 靛玉红类CDK1抑制剂的同源模建、分子对接及3D-QSAR研究[J]. 物理化学学报, 2014, 30(2): 371 -381 .
[3]	乔康, 曾凌晓, 金宏威, 刘振明, 张亮仁. 人类腺苷受体A₃亚型拮抗剂的构效关系分析[J]. 物理化学学报, 2012, 28(06): 1509 -1519 .
[4]	金毅, 王悦, 卞富永, 史强, 葛茂发, 王树, 张兴康, 徐四川. 多巴胺第三受体蛋白三维结构及其活性位点氨基酸残基[J]. 物理化学学报, 2011, 27(10): 2432 -2446 .
[5]	柯艳蓉, 金宏威, 刘振明, 张亮仁. A₁腺苷受体的同源模建及其结构验证[J]. 物理化学学报, 2010, 26(10): 2833 -2839 .
[6]	章媛, 陈亚东, 尤启冬, 邹丽云, 杨燕. 同源模建和分子对接研究HDAC1/HDAC8的选择性[J]. 物理化学学报, 2010, 26(06): 1676 -1686 .
[7]	吕雯, 吕炜, 牛彦, 雷小平. 毒蕈碱型M₁受体的同源模建和分子对接[J]. 物理化学学报, 2009, 25(07): 1259 -1266 .
[8]	赵勇山郑清川张红星楚慧郢孙家钟. 人类丝氨酸消旋酶的同源模建及其与多肽类抑制剂的分子对接[J]. 物理化学学报, 2009, 25(03): 417 -422 .
[9]	刘海春;邹建卫;张兵;庄树林;蒋勇军;俞庆森. 对羟基杏仁酸合成酶三维结构模建及其与底物的分子对接研究[J]. 物理化学学报, 2005, 21(08): 852 -856 .
[10]	赵立峰;丁晓琴;丁俊杰;陈冀胜. α_2A肾上腺素受体的同源模建及与Yohimbine的对接研究[J]. 物理化学学报, 2005, 21(02): 151 -155 .